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Background: Pulmonary sarcomatoid carcinoma is a diagnostically challenging group of tumors. It’s a rare
histologic subtype of non-small cell lung cancer.There are five subgroups of pulmonary sarcomatoid carcinoma,
they are identified as pleomorphic carcinoma, spindle cell carcinoma, giant cell carcinoma, carcinosarcoma, and
pulmonary blastoma. We explored the clinicopathologic features and prognostic factors of this tumor.
Methods: We analyzed retrospectively the clinicopathological data of 51 patients with pulmonary sarcomatoid
carcinoma who were treated in the First Affiliated Hospital of Zhengzhou University, Henan Cancer Hospital and
Henan People Hospital from January 2005 to December 2012. The correlation between prognosis and age, sex,
smoking history, tumor size, TNM staging, and treatment modality was analyzed by the statistical software SPSS
17.0. The survival analysis was conducted using the Kaplan-Meier method. The factors influencing survival were
analyzed using univariate (Log-rank) and multivariate (Cox) models.
Results: The overall survival rates at 1, 2, 3 and 5 years were 45.5%, 35.8%, 28.2% and 20.1%, respectively. Cox
univariate analyses revealed that age, tumor size, T stage, M stage, surgery or not, and postoperative chemotherapy
or not, were prognostic factors. Cox multivariate analysis found that tumor size and M stage were independent
prognostic factors for PSC.
Conclusions: Due to its rarity and the lack of large-scale clinical trial evidence, few studies about PSC have been
reported, its clinical and pathological characteristics remain unclear, and its preoperative diagnosis and investigation
of novel treatment approaches are imperative. In our study, the main factors affecting the prognosis of tumor size
and M staging are the crucial prognostic factors for PSC. Surgical resection and postoperative adjuvant
chemotherapy might result in better prognosis.
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PrognosisBackground
Sarcomatoid carcinoma can occur throughout the body;
however, primary sarcomatoid carcinoma in the lung is
very rare, accounting for 0.1% to 0.4% of all lung malig-
nancies [1]. Pulmonary sarcomatoid carcinoma (PSC) is a
rare histologic subtype of non-small cell lung cancer
(NSCLC) [2]. PSC is defined as poorly differentiated non-
small cell carcinoma that contains a component of* Correspondence: lixingyavip@126.com
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reproduction in any medium, provided the orsarcoma or sarcoma-like elements according to the 2004
World Health Organization [3].
PSC generally runs an aggressive clinical course and may
cause major difficulties in the diagnosis; its rapid preopera-
tive diagnosis is very difficult because of its heterogeneity
[4]. The prognosis remains controversial. Although some
insist that the prognosis of PSC is less favorable than other
NSCLC among postoperative patients [1,5,6], others see no
difference between PSC and other NSCLC [7,8].
This study discusses the clinicopathological features and
prognostic factors for 51 cases of pulmonary sarcomatoid
carcinoma. This retrospective analysis of clinical data,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinicopathological characteristics and survival












Male 43 6 21.7% 1.424 0.233
Female 8 4 21.4%
Age
≤60y 28 8.5 22.4% 4.055 0.044
>60y 23 4 15.1%
Tumor size
≤7 cm 25 29 30.8% 21.789 0.000
>7 cm 26 4 7.7%
Smoking
history
No 18 5 25% 0.622 0.430
Yes 33 6 21.2%
T stage
T1-2 20 32 28.4% 12.423 0.000
T3-4 31 4 14.2%
Lymph node
metastasis
No 27 7 24.2% 2.813 0.093
Yes 24 4 14.3%
M metastasis
No 38 9 26.1% 36.313 0.000
Yes 13 3 0
Surgery or not
Yes 37 7 24.1% 7.800 0.005
No 14 3.5 0
Postoperative
chemotherapy
Yes 19 17 38.4% 4.755 0.029
No 18 5.5 8.5%
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appropriate diagnostic and therapeutic strategies for this
aggressive ‘miniature monster’.
Methods
Ethical approval: Any experimental research were
performed with the approval of ethics committee. Re-
search carried out on humans were in compliance with
the Helsinki Declaration,
1. Patient inclusion criteria: The 51 patients with
pulmonary sarcomatoid carcinoma treated in
Henan Cancer Hospital, Henan People Hospital and
First Affiliated Hospital of Zhengzhou University
between January 2005 and December 2012 were
included in this study. All specimens of these
patients were confirmed by two experienced
pathologists according to the 2004 WHO
classification of PSC. The diagnosis was confirmed
when at least 10% of the tumor contained a
sarcomatoid component consisting of spindle or
pleomorphic giant cells, or both.
2. Clinical data: In these 51 cases, five cases were
carcinosarcoma, one case was pulmonary blastoma,
five cases were spindle cell carcinoma, two cases
were giant cell carcinoma, and the remaining cases
were not diagnosed as a specific subtype of
sarcomatoid carcinoma. Of these cases, 43 were
males, 8 were females, and the male to female ratio
was 5.4:1. Patients ranged in age from 30 to 80 years
with a mean age of 57.8 years. A total of 18 patients
had no history of smoking, 9 cases had a smoking
history of <30 years, and 24 cases had a smoking
history of ≥30 years. Incidence of cough,
expectoration, chest pain, back pain and bloody
sputum are in the majority in this group, and nine
asymptomatic cases were detected via physical
examination. For this group of patients, there were
15 cases involving the left upper lobe, 14 cases
involving the lower lobe, 6 cases involving the right
upper lobe, 4 cases involving the mid-lobe, and 3
cases involving the lower lobe. The remaining cases
had multiple lesions. According to the international
staging of lung cancer, the TNM stage of the 51
resection or biopsy pathologic results were as
follows: 2 cases of Phase I (all Ia), 25 cases of Phase
II (10 cases of IIa and 15 cases of IIb), 14 cases of
Phase III (all IIIa), and 10 cases of Phase IV.
3. Follow-up: All patients were followed up (outpatient,
telephone, or follow-up letter investigation) until 22
December 2012. Follow-up was 1 to 57 months,
with median follow-up being 6 months. At the end
of the observation, 31 patients had died and 20
patients had survived.4. Statistical methods: Data were entered, analyzed, and
processed using SPSS 17.0 statistical software. Data was
conducted using the Kaplan-Meier method and draw
the survival curve, Log rank method of prognostic
factors in univariate analysis test, Cox model for
multivariate analysis. The inspection level α = 0.05.
Results
1. Pathological results: Of the patients, 3 of 9 cases
that were biopsied using a fiber endoscope were
confirmed by pathological examination, and 12 of 18
cases were confirmed by computed tomography
Figure 1 The survival curve of 51 patients. a) Different age patients with PSC survival curve comparison. b) Different tumor size patients with
PSC survival curve comparison. c) Different T stage patients with PSC survival curve comparison. d) Different M stage patients with PSC survival
curve comparison. e) Whether or not surgery PSC patients survival curves comparison. f) Whether postoperative chemotherapy in patients with
PSC survival curve comparison. PSC, pulmonary sarcomatoid carcinoma.
Table 2 Multivariate Cox model analysis of effects of
pulmonary sarcomatoid carcinoma (PSC) prognosis
Variable Β Wald RR 95% CI P
Tumor size 1.369 7.743 3.931 1.499 to 10.310 0.005
M metastasis 1.803 4.622 6.067 1.173 to 31.388 0.032
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cases were not correctly diagnosed before surgery
pathology results. Tumor size was calculated by the
maximum diameter. The tumor sizes of this group
were approximately 2 to 18.0 cm with an average size
of 8 cm; 25 cases were ≤7 cm and 26 cases were >7
cm. Three of the 51 patients had neuroendocrine
differentiation and one patient had large cell
neuroendocrine carcinoma CD56 +.
2. Immunohistochemistry: Immunohistochemistry was
performed using antibodies including Vim, CK, P63,
S-100, Ki67, CK7, EMA, TTF-1, CK5/6, Syn etcetera
by (streptavidin-perosidase( SP) method. Among
those antibodies, CK and Vim showed the highest
expression, 92.9% (39/42) and 90.5% (38/42),
respectively; EMA showed a moderate positive,
90.0% (9/10); TTF-1, P63, CK5/6 and CK7 were
positive at 33.3% (9/27), 43.8% (7/16), 42.3% (11/26)
and 65.4% (17/26), respectively; and S-100 and Syn
were expressed in the lowest amounts, 10.5% (2/19)
and 20.0% (3/15), respectively.
3. Treatment methods: A total of 37 patients
underwent ipsilateral lobectomy or pneumonectomy,
combined with mediastinal lymph node dissection.
After surgery, 19 cases received chemotherapy. The
chemotherapy drugs used were gemcitabine,
vinorelbine, paclitaxel, docetaxel, cisplatin and other
routine chemotherapy drugs used for NSCLC.
4. Survival analysis: The average survival time of the
patients was 13.3 months, and the median survivaltime was 6 months (95% confidence interval, 1.6 to
18.4 months). The 1-, 2-, 3- and 5-year overall
survival rates were 45.5%, 35.8%, 28.2% and 20.1%,
respectively. Statistical analysis was carried out on
the clinical characteristics including gender, age,
tumor size, smoking history and treatment factors
and prognosis. The results are shown in Table 1.
5. Prognostic factors analysis results: Univariate
analysis (Figure 1a-f ) showed that prognosis of the
patients was influenced by age, tumor size, T stage,
metastatic status, surgery or not, and postoperative
chemotherapy or not (P <0.05, Table 1). However,
multivariate analysis showed that tumor size
(P = 0.005) and metastatic status (P = 0.032) are
independent prognostic factors (Table 2).
Discussion
PSC occurs mostly in men in their sixth and seventh de-
cades, except for the pulmonary blastoma subtype, which
occurs equally in men and women and frequently in the
fourth decade [9,10]. It shows prevalence among male
smokers, with an average age at presentation of 60 years
and who have a history of moderate to heavy tobacco
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ratio was 5.4:1 and 63.0% (29/46) of the patients have a
history of smoking; however, the smoking history did not
have a significant influence on the prognosis (P = 0.430).
Compared to other histologic subtypes, PSC behaves
in an aggressive way. In the major published series of
PSC, no specific signs or symptoms have been found
when compared with other typical NSCLC [11-15]. The
preoperative diagnosis of PSC is very difficult. Although
PSC may sometimes be diagnosed on cytological prepa-
rations, surgical or biopsy specimens are necessary to
obtain a definitive diagnosis because of the heterogeneity
of PSC. In this group, the preoperative misdiagnosis rate
was 70.6% (36/51). Someone raised [16], A modified
vimentin histologic score (M-VHS) could be an effective
diagnostic tool for this cancer, as to whether can be ap-
plied to clinical needs further large-scale studies. Some
reports [10,16-18] show that positron emission tomog-
raphy (PET) uptake is much higher in sarcomatoid car-
cinoma than in other NSCLC (P <0.0001), which means
a PET scan may effectively identify PSC, but further con-
firmation still depends on pathological diagnosis.
The average survival of patients with PSC was 13.3
months in our study, which is slightly longer than the 11
months that is reported in other published series [12]. It is
possible that multimodality therapeutic approach may also
have contributed to a better prognosis for advanced pa-
tients. The 1-, 2-, 3- and 5-year overall survival rates in
this group were 45.5%, 35.8%, 28.2% and 20.1%, respect-
ively. Multivariate analysis of prognostic factors revealed
that the main factors affecting prognosis are tumor size
and M staging.
The treatment principle for pulmonary sarcomatoid
carcinoma is similar with other non-small cell lung can-
cer. In this study, surgery or not (P = 0.005) and postop-
erative chemotherapy or not (P = 0.029) both have
significant impact on prognosis on a statistical level.
Early surgery is the preferred treatment for PSC, for
which the postoperative adjuvant chemotherapy can be
performed. Given the current status of epidermal
growth factor receptor tyrosine kinase inhibitor (EGFR-
TKI) in treatment of NSCLC, could be considered for
treatment of PSC? Until now, innovative treatments
such as monoclonal antibodies, which are target epider-
mal growth factor receptor mutations, have shown no
definitive effect on the outcome [17-19]. It needs more
large population clinical studies to prove whether
EGFR-TKI can bring the Gospel for patients with PSC
or not. Tsao AS and his colleague show that PDGFR-b
has a higher expression and an increase of gene copy
number in PSC compared with other NSCLC, which
suggests that perhaps PDGFR-b would become a new
therapeutic target [20]. These studies suggest a new re-
search direction for PSC treatment.The study presents several limitations that must be con-
sidered when interpreting the results. First, the population
in this study was small because the disease is rare. Second,
this study includes a wide variety of patients. Some pa-
tients underwent curative resection, while some did not
because of advanced disease. Some patients underwent
chemotherapy, while some did not because of economic
conditions. Third, the study includes only eight female pa-
tients. Future studies with larger patient population must
re-evaluate the influence of gender so that we can obtain
statistical power.
Conclusions
In summary, many patients are easily misdiagnosed be-
fore accepting surgery, so an accurate preoperative histo-
logical diagnosis is imperative. Limited experience in
diagnosis, treatment and prognosis of PSC still exists be-
cause the disease is rare and because there is a lack of
large-scale clinical trial evidence. Because further re-
search in diagnosis and treatment is urgent, we hope
that the reports about PSC will gradually increase in
order to facilitate clinical doctors to manage the disease
and benefit the patients.
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